Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors

Status: Active

Description

This is a multicenter, open label, Phase 1 / 2 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 (larotrectinib) will be administered orally (PO) twice daily (BID), with the dose adjusted by body surface area (BSA).

Eligibility Criteria

Inclusion Criteria

  • Pediatric patients ≥ 1 day old on Cycle 1 Day 1 (C1D1)
  • Phase 1: Birth through 21 years of age at C1D1 with a locally advanced or metastatic solid tumor or primary CNS tumor that has relapsed, progressed or was nonresponsive to available therapies and for which no standard or available systemic curative therapy exists, or infants from birth and older with a diagnosis of malignancy and with a documented NTRK fusion that has progressed or was nonresponsive to available therapies, and for which no standard or available curative therapy exists, or patients with locally advanced infantile fibrosarcoma who would require, in the opinion of the Investigator, disfiguring surgery or limb amputation to achieve a complete surgical resection. The Phase I dose escalation cohorts are closed to enrollment. In addition to the above stated Inclusion Criteria, patients eligible for enrollment into this cohort must have a malignancy with a documented NTRK gene fusion with the exception of patients with infantile fibrosarcoma, congenital mesoblastic nephroma or secretory breast cancer. Patients with infantile fibrosarcoma, congenital mesoblastic nephroma or secretory breast cancer may enroll into this cohort with documentation of an ETV6 rearrangement by FISH or RT-PCR or a documented NTRK fusion by NGS.
  • Phase 2 only: Infants from birth and older at C1D1 with a locally advanced or metastatic infantile fibrosarcoma, patients with locally advanced infantile fibrosarcoma who would require, in the opinion of the Investigator, disfiguring surgery or limb amputation to achieve a complete surgical resection or birth through 21 years of age at C1D1 with a locally advanced or metastatic solid tumor or primary CNS tumor that has relapsed, progressed or was nonresponsive to available therapies and for which no standard or available systemic curative therapy exists with a documented NTRK gene fusion (or in the case of infantile fibrosarcoma, congenital medoblastic nephroma or secretory breast cancer with documented ETV6 rearrangement by FISH or RT-PCR or a documented NTRK fusion by NGS) (identified through molecular assays as routinely performed at CLIA or other similarly-certified laboratories) or (including Expansion Phase) potential patients older than 21 years of age with a tumor diagnosis with histology typical of a pediatric patient and an NTRK fusion may be considered for enrollment following discussion between the local site Investigator and the Sponsor's Medical Monitor. Patients with NTRK-fusion positive benign tumors are also eligible.
  • Karnofsky (those 16 years old or older) or Lansky (those younger than 16 years) performance score of at least 50
  • Adequate hematologic function: Absolute neutrophil count (ANC) ≥ 1.0 109/L, platelet count ≥ 100.0 109/L and hemoglobin ≥ 8.0 g/dL (patients with bone marrow involvement will not be evaluable for hematologic DLT and can enroll with ANC ≥ 0.75 109/L, platelet count ≥ 50.0 109/L and hemoglobin ≥ 8.0 g/dL)
  • Adequate hepatic function: Bilirubin (sum of conjugated + unconjugated) ≤ 2.5 upper limit of normal (ULN) for age (patients with documented Gilbert's Disease may be enrolled with Sponsor approval).
  • Adequate renal function: Estimated glomerular filtration rate ≥ 30 mL/minute using the Cockroft-Gault formula or: a serum creatinine based on age/gender as outlined in the protocol
  • Requirement of highly effective birth control methods with a failure rate of less than 1% per year for male subjects. Also defined sexual abstinence as a birth control method per CTFG guidelines.

Exclusion Criteria

  • Investigational agent, anticancer therapy, or major surgery within 14 days (2 weeks) prior to C1D1
  • Clinically significant active cardiovascular disease or history of prolonged QT interval corrected for heart rate (QTc)
  • Current treatment with a strong cytochrome P450 (CYP) 3A4 inhibitor or inducer (EIAEDs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed)
  • Phase 2 Only: Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting TRK, including entrectinib, crizotinib and lestaurtanib. Patients who received a TRK inhibitor for less than 28 days of treatment and discontinued because of intolerance remain eligible.

Locations & Contacts

California

Los Angeles
Children's Hospital Los Angeles
Status: Approved
Contact: Shivam Patel Email: shipatel@chla.usc.edu
UCLA / Jonsson Comprehensive Cancer Center
Status: Active
Contact: Joanna Margaret Balducci Email: jbalducci@mednet.ucla.edu
Palo Alto
Lucile Packard Children's Hospital Stanford University
Status: Active
Name Not Available

Massachusetts

Boston
Boston Children's Hospital
Status: Active
Contact: Cecilia Carlowicz Email: cecilia_carlowicz@dfci.harvard.edu
Dana-Farber Cancer Institute
Status: Active
Contact: Cecilia Carlowicz Email: cecilia_carlowicz@dfci.harvard.edu

New York

New York
Memorial Sloan Kettering Cancer Center
Status: Active
Name Not Available

Tennessee

Memphis
St. Jude Children's Research Hospital
Status: Active
Contact: Alberto S. Pappo Email: info@stjude.org

Texas

Dallas
UT Southwestern / Simmons Cancer Center-Dallas
Status: Active
Contact: Alison Patterson Email: alison.patterson@childrens.com

Washington

Seattle
Seattle Children's Hospital
Status: Active
Name Not Available

Trial Objectives and Outline

This is a multicenter, open label, Phase 1/2 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 (larotrectinib) will be administered orally (PO) twice daily (BID), with the dose adjusted by body surface area (BSA). Dose Escalation Phase has completed enrollment and it has been determined that the maximum dose for the Phase 1 Expansion and Phase 2 portions of the study will be no higher than the recommended Phase 2 dose of 100 mg BID in the adult Phase 2 trial, regardless of the patient's BSA. Phase 1 Expansion and Phase 2 portions of the study are currently enrolling.

Trial Phase & Type

Trial Phase

Phase I/II

Trial Type

Treatment

Lead Organization

Lead Organization
Loxo Oncology, Inc.

Trial IDs

Primary ID LOXO-TRK-15003
Secondary IDs NCI-2016-00678
Clinicaltrials.gov ID NCT02637687